Building Blocks

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>PB-22 is a synthetic cannabinoid, which can be classified as a CB1 receptor agonist. It is one of the many cannabinoids that have been created in an attempt to circumvent drug laws by creating compounds that are similar to those found in cannabis but have different chemical structures. PB-22 has shown to increase locomotor activity and stimulate the cb1 receptor in mice. Magnetic resonance spectroscopy (MRS) and assays were used to determine the binding affinity of PB-22 for the CB1 receptor. The MRS data showed that PB-22 bound with high affinity to the CB1 receptor and had a lower affinity for CB2 receptors. This suggests that PB-22 may be more potent than other synthetic cannabinoids, such as JWH-018 and CP 55,940, which bind better with CB2 receptors than CB1 receptors.<br>PB-22 is an analog of JWH-073 and has been shown to have a stronger effect on locomotor activity than JWH</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>6-Amino-[1,2,4]triazolo[1,5-a]pyridine is a drug that binds to the acetylcholine receptor and blocks the action of acetylcholine. It is used in psychiatry to treat dysfunction. 6-Amino-[1,2,4]triazolo[1,5-a]pyridine may also be used as an adjunct treatment for psychiatric disorders such as schizophrenia or depression. The drug has been shown to have allosteric properties in the muscarinic acetylcholine receptor and has been demonstrated to be a modulator at this site. 6-Amino-[1,2,4]triazolo[1,5-a]pyridine may also act on the muscarinic acetylcholine receptors in the central nervous system by blocking acetylcholine binding.</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>2-Ethynyl-4-methylthiazole is a cell-based kinase inhibitor that binds to the ATP binding site on the enzyme and inhibits phosphorylation. It was shown to inhibit cell growth in vitro by interfering with the production of TGF-β, activin, and other growth factors. The inhibitory activity of 2-Ethynyl-4-methylthiazole is selective for receptor kinases and is not effective against alk5 kinase. This drug has been shown to be an inhibitor of cellular growth in vitro and may be useful for the treatment of cancer.</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Methyl 4-hydroxy-2-sulfanylquinoline-3-carboxylate (MSQ) is a synthetic molecule that has shown to have antiviral activity against the hepatitis B virus. This compound is a competitive inhibitor of the virus and prevents it from infecting cells. MSQ has also been shown to inhibit other viruses, such as herpes simplex virus, influenza A and C, rotavirus, and human immunodeficiency virus type 1 (HIV-1). The high inhibition of MSQ can be attributed to its ability to form hydrogen bonds with the amino acid residues in viral proteins. Additionally, MSQ interacts with anions in the active site of the enzymes that are necessary for viral replication through alkylation reactions.<br>MSQ has been found to be selective for influenza A and C by binding at different sites on the enzyme compared to other compounds like zanamivir and oseltamivir. The single-crystal x</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>2-Cyano-5-fluorophenol is an organic compound that is used as a precursor to medicines and other chemicals. It reacts with calcium hydroxide in water to form 2-cyano-5-hydroxyfluorobenzene, which can be hydrolyzed to form 2-cyano-5-chlorofluorobenzene. This compound can also react with sodium hydroxide to produce sodium cyanate, which can be hydrolyzed to form sodium chloride and hydrogen cyanide gas. The alkali metal ions are needed for this reaction, which is why the product should not be exposed to water or moisture. 2-Cyano-5-fluorophenol has been shown to have liquid crystal properties and is used in the production of certain types of polymers. 2Cyano-5Fluorophenol crystals are also used in some medicines such as acetaminophen (paracetamol).</p>

<p>Versatile small molecule scaffold</p>

<p>2-Bromo-3,3,3-trifluoro-1-propene is a chemical compound that has been synthesized in an asymmetric reaction. The reactant is bromopropane and the product is 2,2,2-trifluoropropene. The methylene group on the propene molecule is activated by the nucleophilic attack of a fluoride ion from hydrogen fluoride to form a cavity with a highly strained bond. The kinetic study of this reaction revealed that the activation energy for the reaction is 42 kJ/mol. Palladium-catalyzed coupling reactions are catalyzed by palladium and require nonpolar solvents such as toluene or dichloromethane. This type of reaction has been shown to be exothermic with an isolated yield of 1%.</p>

<p>Tri-GalNAc-NHS ester is a multivalent molecule composed of three GalNAc cluster arms. It is a protein degrader and a ligand of the asialoglycoprotein receptor (ASGPR) used for the development of targeted therapies for liver diseases. The GalNAc arms enable high-affinity binding to the ASGPR on hepatocyte surfaces. The crucial functional group, N-hydroxysuccinimide (NHS) ester, is known for its ease of conjugation with various biomolecules possessing amine (NH2) groups. This biocompatible reaction strategy allows the design and development of targeted conjugates such as drug-GalNAc conjugates, siRNA delivery vehicles, or probes for ASGPR imaging in the liver.</p>